McCoy E C, Petrullo L A, Rosenkranz H S
Mutat Res. 1980 Sep;79(1):33-43. doi: 10.1016/0165-1218(80)90145-7.
The antimicrobial agents nalidixic acid and novobiocin, both inhibitors of DNA gyrase, preferentially inhibit the growth of DNA repair-deficient Escherichia coli, Salmonella typhimurium and Bacillus subtilis. On the other hand, these agents exhibit no demonstrable mutagenicity for S. typhimurium and E. coli even when tested under conditions designed to take the metabolic properties of these agents into consideration. Novobiocin and nalidixic acid are widely used in animal and human medicine and further studies to assess their genetic and carcinogenic potentials appear to be in order.
抗菌剂萘啶酸和新生霉素均为DNA回旋酶抑制剂，它们优先抑制DNA修复缺陷型的大肠杆菌、鼠伤寒沙门氏菌和枯草芽孢杆菌的生长。另一方面，即使在设计时考虑到这些药剂代谢特性的条件下进行测试，这些药剂对鼠伤寒沙门氏菌和大肠杆菌也未表现出明显的致突变性。新生霉素和萘啶酸在动物和人类医学中广泛使用，因此开展进一步研究以评估它们的遗传和致癌潜力似乎是恰当的。
